background
object
convent
cell
cultur
cc
limit
clinic
util
result
extend
incub
period
often
requir
viru
isol
altern
methodolog
introduc
effort
improv
turnaround
time
one
system
rmix
tm
shell
vial
discuss
herein
studi
object
establish
rmix
tm
test
paramet
compar
direct
antigen
test
dat
cc
b
assess
technic
aspect
cost
rmix
tm
high
volum
clinic
virolog
laboratori
studi
design
prospect
analysi
respiratori
sampl
submit
clinic
virolog
laboratori
novemb
april
perform
specimen
inocul
onto
rmix
tm
shell
vial
sv
cc
tube
subset
also
underw
dat
influenza
b
andor
rsv
retrospect
estim
cost
analysi
made
result
total
sampl
includ
studi
collect
reveal
total
virus
sensit
rmix
tm
seven
major
respiratori
virus
rang
compar
cc
dat
mean
time
detect
ttd
vari
day
addit
virus
picornavirus
cmv
isol
hsv
isol
detect
cc
alon
conclus
rmix
tm
system
similar
sensit
cc
detect
parainfluenza
influenza
ab
dramat
reduc
ttd
furthermor
significantli
sensit
produc
time
result
rsv
cc
yet
neither
method
offer
diagnost
benefit
rapid
dat
rsv
detect
sensit
rmix
tm
adenoviru
appear
significantli
lower
cc
lastli
methodolog
rmix
tm
must
remain
place
circumst
identif
potenti
viral
respiratori
pathogen
includ
herpesvirus
picornavirus
desir
recent
year
clinic
virolog
laboratori
wit
increas
number
commerci
avail
viru
detect
system
vari
consider
term
abbrevi
cc
cell
cultur
ci
confid
interv
cmv
cytomegaloviru
dat
direct
antigen
test
eia
enzym
immunoassay
hemadsorpt
hsv
herp
simplex
viru
immunofluoresc
npv
neg
predict
valu
pcr
polymeras
chain
reaction
ppv
posit
predict
valu
rsv
respiratori
syncyti
viru
sv
shell
vial
tn
true
neg
tp
true
posit
ttd
time
detect
methodolog
effici
accuraci
cost
desir
faster
better
cheaper
result
continu
provid
impetu
new
test
develop
improv
one
arena
often
yield
shortcom
anoth
thu
laboratori
director
face
difficult
decis
regard
assay
implement
numer
factor
need
consid
least
overal
impact
patient
care
respect
diagnost
test
pathogen
respiratori
virus
cell
cultur
cc
tradit
consid
gold
standard
refer
method
yolken
et
al
one
major
disadvantag
approach
howev
extend
incub
period
often
requir
viru
isol
result
unavail
clinician
initi
stage
patient
manag
shetti
et
al
addit
test
includ
enzym
immunoassay
eia
immunofluoresc
assay
direct
antigen
test
dat
johnston
siegel
reina
et
al
shetti
et
al
weinberg
walker
shell
vial
techniqu
engler
preuss
schirm
et
al
nucleic
acid
amplif
test
kehl
et
al
templeton
et
al
weinberg
et
al
introduc
viral
diagnost
armamentarium
logic
rational
rapid
detect
may
favor
influenc
patient
manag
lead
reduct
antibiot
usag
shorter
less
costli
hospit
fewer
extran
laboratori
test
order
better
cohort
capabl
infect
control
measur
better
util
antivir
therapi
number
investig
address
one
issu
directli
employ
dat
methodolog
basi
patient
outcom
comparison
made
adcock
et
al
barenfang
et
al
byington
et
al
noyola
demmler
woo
et
al
consid
paramet
molecular
test
util
polymeras
chain
reaction
pcr
perform
exceedingli
well
detect
respiratori
virus
like
supersed
cell
cultur
new
gold
standard
kehl
et
al
templeton
et
al
weinberg
et
al
yet
mani
clinic
laboratori
equip
capabl
present
direct
antigen
test
inexpens
rel
pcr
offer
benefit
simplic
short
turnaround
time
assay
often
consider
lower
sensit
cell
cultur
howev
shell
vial
techniqu
incorpor
speed
specif
viru
detect
immunofluoresc
antibodi
sensit
viru
propag
cell
monolay
provid
attract
option
term
perform
rapid
cost
one
commerci
avail
system
rmix
tm
shell
vial
system
diagnost
hybrid
inc
dhi
athen
oh
combin
epitheli
cell
deriv
mink
lung
human
adenocarcinoma
cell
line
order
support
replic
sever
respiratori
virus
includ
influenza
b
rsv
adenoviru
serotyp
parainfluenza
viru
analyt
sensit
st
georg
et
al
cost
analysi
barenfang
et
al
perform
characterist
dunn
et
al
fong
et
al
weinberg
et
al
rmix
tm
shell
vial
system
address
medic
literatur
present
studi
conduct
effort
substanti
data
larg
tertiarycar
hospit
laboratori
entir
respiratori
viru
season
use
tradit
cc
dat
method
comparison
b
assess
technic
aspect
cost
rmix
tm
order
determin
feasibl
replac
cc
appropri
label
adequ
transport
nasal
wash
nasopharyng
aspiratesswab
throat
swab
submit
dat
andor
respiratori
viral
cultur
univers
texa
medic
branch
clinic
microbiolog
laboratori
novemb
april
includ
analysi
specimen
cultur
use
convent
tube
monolay
method
rmix
tm
shell
vial
system
wherea
dat
perform
upon
request
specimen
accept
outpati
clinic
urgent
care
facil
utmb
emerg
depart
inpati
ward
accept
specimen
includ
swab
receiv
viral
transport
medium
remel
lenexa
ks
fluid
sampl
ie
wash
aspir
receiv
directli
transport
medium
steril
pb
aliquot
eia
test
order
made
prior
centrifug
step
g
min
c
follow
centrifug
portion
supernat
frozen
c
possibl
futur
use
remaind
util
cultur
shell
vial
detail
direct
test
order
perform
follow
resuspens
cell
pellet
ml
steril
pb
choic
dat
methodolog
depend
upon
time
specimen
arriv
laboratori
rapid
dat
request
sampl
store
c
process
time
detect
ttd
virus
gener
use
specimen
process
start
point
resuspend
cell
pellet
spot
onto
glass
slide
fix
aceton
flourophoreconjug
monoclon
antibodi
use
rsv
influenza
influenza
b
imagen
dako
carpinteria
ca
detect
evan
blue
counterstain
provid
nuclear
detail
determin
specimen
adequacyneg
spot
contain
fewer
epitheli
cell
report
insuffici
eia
test
immunochromatograph
kit
rsv
influenza
b
binax
portland
use
accord
manufactur
instruct
standard
tube
monolay
primari
rhesu
monkey
kidney
cell
rhmk
two
tube
human
lung
carcinoma
cell
one
tube
diploid
human
embryon
lung
cell
two
tube
dhi
use
convent
respiratori
viru
cultur
ml
volum
sampl
inocul
tube
adsorb
h
cell
incub
roller
drum
c
c
replic
rhmk
tube
screen
cytopath
effect
cpe
daili
day
everi
day
addit
day
hemadsorpt
use
ml
solut
guinea
pig
erythrocyt
perform
least
twice
rhmk
replic
cell
spot
posit
tube
stain
unconjug
monoclon
antibodi
influenza
b
parainfluenza
serotyp
bartel
triniti
biotech
wicklow
ireland
hadneg
specimen
spot
stain
individu
monoclon
antibodi
rsv
adenoviru
hsv
cmv
bartel
triniti
biotech
polyclon
antibodi
panenteroviru
coxsacki
b
echoviru
chemicon
intern
temecula
ca
base
cpe
andor
cell
tropism
slide
stain
conjug
primari
antibodi
cmv
hsv
enteroviru
read
directli
indirect
assay
spot
stain
flourophoreconjug
secondari
antimurin
antibodi
bartel
triniti
biotech
shell
vial
cultur
setup
recommend
manufactur
briefli
rmix
tm
shell
vial
inocul
ml
specimen
cc
final
volum
inoculum
vari
depend
upon
total
amount
specimen
receiv
howev
equal
volum
sampl
ad
cc
rmix
tm
cultur
assayspecif
refe
medium
util
dhi
shell
vial
centrifug
g
min
incub
c
stationari
rack
flourophoreconjug
antirespiratori
viru
antibodi
cocktail
dhi
use
broadspectrum
screen
stain
h
posit
replic
shell
vial
prepar
confirm
stain
use
individu
monoclon
antibodi
rsv
adenoviru
influenza
b
parainfluenza
serotyp
dhi
broadspectrum
stain
neg
third
replic
vial
discard
given
high
analyt
specif
rate
assay
includ
studi
chose
defin
true
posit
posit
valu
regardless
methodolog
base
definit
use
individu
posit
rate
determin
overal
preval
sensit
neg
predict
valu
npv
determin
virusmethodolog
combin
comparison
proport
perform
use
chi
squar
analys
gener
twotail
p
valu
consid
signific
nearli
period
studi
total
sampl
process
cc
rmix
tm
shell
vial
assay
rapid
dat
perform
subset
sampl
patient
age
rang
week
year
mean
year
median
year
specimen
receiv
collect
patient
year
age
specimen
includ
analysi
total
virus
detect
one
method
result
overal
posit
rate
figur
includ
eight
sampl
dual
viru
infect
detect
tabl
frequent
detect
viru
studi
period
rsv
n
follow
influenza
ab
n
adenoviru
n
parainfluenza
picornavirus
n
tabl
ii
sensitivitynpv
detect
rsv
rmix
tm
significantli
higher
cc
respect
p
mean
ttd
rsv
posit
specimen
rmix
tm
shell
vial
assay
day
compar
day
requir
cc
hand
dat
identifi
rsvposit
sampl
eia
dfa
result
significantli
greater
sensitivitynpv
rsv
either
cc
rmix
tm
p
addit
result
report
within
h
specimen
process
sensitivitynpv
detect
adenoviru
significantli
higher
cc
rmix
tm
respect
p
mean
ttd
cc
day
versu
day
rmix
tm
interestingli
cc
requir
averag
day
isol
adenoviru
strain
detect
rmix
tm
system
wherea
mean
ttd
isol
identifi
cc
day
sensitivitynpv
detect
parainfluenza
isol
cc
rmix
tm
differ
well
differ
detect
individu
serotyp
signific
addit
picornaviru
isol
herpesviru
isol
recov
cc
tabl
total
specimen
contain
either
influenza
n
b
n
identifi
studi
cc
rmix
tm
dat
eia
dfa
tabl
sensit
confid
interv
combin
influenza
ab
detect
cc
rmix
tm
dat
respect
tabl
statist
differ
sensit
two
cultur
method
identifi
yet
mean
ttd
rmix
tm
day
shorter
cc
sensit
influenza
ab
detect
dat
differ
significantli
compar
either
cultur
methodolog
analysi
influenza
b
data
subset
individu
yield
similar
result
subanalysi
individu
dat
methodolog
data
shown
routin
laboratori
protocol
incorpor
cultur
datposit
sampl
throughout
epidem
season
chose
analyz
separ
cultur
result
subset
specimen
either
datneg
dat
perform
due
lack
request
cultur
posit
rsv
influenza
ab
respect
either
rmix
tm
cc
tabl
analyz
fashion
statist
differ
sensit
rmix
tm
cc
detect
rsv
influenza
ab
note
mean
ttd
rmix
tm
remain
shorter
cc
averag
day
faster
influenza
ab
rsv
respect
cultur
protocol
place
studi
period
howev
overal
detect
rate
either
cc
rmix
tm
would
effect
reduc
illustr
fig
rel
proport
virus
detect
cultur
alon
would
differ
comparison
proport
detect
three
methodolog
result
rsv
influenza
ab
parainfluenza
compris
total
number
virus
detect
method
fig
repres
virus
detect
cultur
alon
fig
put
differ
specimen
cultur
would
sole
manner
viru
detect
eg
dat
neg
dat
request
gave
similar
overal
posit
rate
rsv
hsv
cmv
well
influenza
ab
picornavirus
adenoviru
parainfluenza
fig
equivoc
result
occasion
obtain
rmix
tm
screen
pool
antibodi
posit
confirm
stain
replic
sv
individu
antibodi
neg
total
specimen
gave
initi
equivoc
result
h
h
identifi
virusposit
cc
andor
dat
neg
rmix
tm
upon
repeat
stain
five
adenoviru
four
influenza
two
parainfluenza
thirteen
sampl
neg
cc
dat
rmix
tm
remain
nine
sampl
initi
equivoc
h
becam
posit
h
upon
repeat
stain
individu
virusspecif
antibodi
one
adenoviru
two
influenza
four
rsv
two
parainfluenza
isol
seven
nine
isol
concomitantli
identifi
cc
andor
dat
overal
rmix
tm
system
well
accept
among
laboratori
personnel
due
perform
eas
timesav
given
two
cultur
protocol
use
studi
found
neglig
differ
setup
time
eg
specimen
process
inocul
centrifug
step
etc
baselin
materi
cost
ie
cell
monolayersshel
vial
two
cultur
methodolog
primari
differ
cost
note
immunofluoresc
reagent
overal
technologist
time
calcul
spent
approxim
rmix
tm
per
specimen
approxim
cc
per
specimen
immun
reagent
entir
studi
period
partial
compens
save
technologist
h
per
specimen
rmix
tm
versu
h
per
specimen
cc
repres
differ
per
specimen
base
upon
h
salari
item
either
repres
nomin
cost
difficult
calcul
due
use
assay
result
indic
rmix
tm
system
outperform
cc
respect
sensit
mean
ttd
rsv
tabl
compar
dat
howev
neither
rmix
tm
cc
provid
sensit
time
result
suggest
dat
remain
test
choic
rsv
institut
given
liabil
rsv
prior
report
demonstr
dat
frequent
detect
uncultiv
rsv
johnston
siegel
kellogg
reason
doubt
rsvposit
sampl
detect
dat
alon
actual
true
posit
inde
investig
rmix
tm
system
illustr
benefit
dat
rsv
detect
dunn
et
al
fong
et
al
yet
given
possibl
small
number
rsvposit
sampl
detect
dat
may
fals
posit
rule
slightli
underestim
sensit
rsv
detect
cc
sv
addit
pediatricag
patient
overrepres
data
b
shown
harbor
higher
rsv
titer
henc
test
posit
dat
frequent
adult
kellogg
draw
conclus
present
studi
regard
appropri
test
rsv
adult
popul
found
rmix
tm
shell
vial
system
perform
quit
favor
comparison
cc
detect
influenza
ab
parainfluenza
potenti
signific
reduct
mean
ttd
achiev
without
appreci
compromis
sensit
tabl
surprisingli
comparison
sensit
influenza
ab
dat
either
cultur
methodolog
reveal
statist
differ
influenza
viru
gener
consid
labil
rsv
scenario
wherein
dat
sole
posit
assay
viru
seem
somewhat
less
like
review
data
indic
dat
posit
influenza
ab
perform
eia
unconfirm
either
cultur
method
specul
result
may
fals
posit
therefor
decreas
calcul
sensit
cultur
system
supplement
test
eg
rtpcr
andor
detail
inform
eg
durat
dat
cultur
setup
might
corrobor
suspicion
readili
avail
one
limit
rmix
tm
shell
vial
system
appear
lower
sensit
detect
adenoviru
clinic
sampl
report
huang
turchek
st
georg
et
al
demonstr
similar
detect
rate
analyt
sensit
adenoviru
isol
rmix
tm
shell
vial
harvest
h
postinocul
compar
shell
vial
convent
cc
method
howev
two
studi
util
store
patient
sampl
previous
test
posit
ifa
b
dilut
passag
viru
contrast
two
prospect
studi
use
fresh
nonpassag
patient
sampl
report
low
sensit
rate
adenoviru
similar
present
studynam
base
isol
respect
dunn
et
al
weinberg
et
al
author
conclud
abbrevi
incub
period
h
differ
inoculum
volum
ml
versu
ml
may
account
observ
low
sensit
valu
yet
variabl
account
observ
adenoviru
sensit
extend
incub
period
rmix
tm
shell
vial
h
b
use
ident
inoculum
volum
specimen
cc
rmix
tm
still
lower
sensit
observ
rmix
tm
could
due
low
viral
titer
sampl
particularli
given
mean
ttd
cc
sampl
detect
rmix
tm
day
case
extend
incub
shell
vial
beyond
h
may
result
increas
recoveri
rate
although
seem
us
defeat
overal
purpos
shell
vial
techniqu
lastli
differ
antibodi
reagent
util
rmix
tm
screenconfirm
dhi
cc
confirm
bartel
triniti
biotech
exclud
unlik
possibl
differ
observ
adenoviru
sensit
two
cultur
system
partli
attribut
inher
antigen
specif
virusspecif
monoclon
antibodi
other
previous
describ
barenfang
et
al
dunn
et
al
also
encount
number
clinic
sampl
appear
virusposit
initi
rmix
tm
screen
neg
individu
antibodi
stain
perform
day
specimen
virusposit
cc
andor
dat
rmix
tm
neg
three
methodolog
nine
ultim
identifi
viru
posit
repeat
rmix
tm
confirm
stain
viru
season
progress
staff
becam
attun
fact
weak
posit
screen
often
confirm
minor
modif
sv
protocol
institut
confirm
weakli
posit
screen
day
postpon
day
inde
number
equivoc
sampl
decreas
studi
progress
abl
confirm
six
virusposit
sampl
day
may
otherwis
gone
undetect
rmix
tm
chosen
extend
incub
equivoc
sampl
day
addit
h
ie
perform
confirm
stain
h
postinocul
may
recov
virus
detect
method
base
upon
rel
proport
virus
identifi
studi
fig
replac
cc
rmix
tm
might
seem
justifi
given
isol
ie
rsv
influenza
ab
parainfluenza
rmix
tm
clearli
outperform
cc
term
sensit
andor
mean
ttd
howev
found
major
virus
detect
elimin
datposit
specimen
ie
sampl
cultur
would
perform
usual
laboratori
protocol
readili
identifi
cc
fig
fact
use
rmix
tm
system
place
cc
exclus
followup
method
dat
studi
would
result
reduct
overal
cultiv
rate
clinic
relev
herpesviru
picornaviru
isol
studi
unknown
virus
implic
respiratori
diseas
among
certain
popul
de
la
hoz
et
al
ghosh
et
al
greenberg
furthermor
number
less
common
respiratori
virus
includ
metapneumoviru
strain
coronaviru
measl
mump
like
recogn
cc
shell
vial
would
seem
reason
laboratori
retain
form
convent
cc
possibl
technic
logist
standpoint
implement
rmix
tm
set
larg
clinic
virolog
laboratori
appeal
potenti
costeffect
found
overal
cost
rmix
tm
system
use
describ
protocol
slightli
higher
per
sampl
current
cc
protocol
take
consider
mark
reduct
labor
requir
former
averag
reductionspecimen
shell
vial
system
addit
advantag
includ
simplic
methodolog
less
depend
experi
discern
cpe
importantli
cost
estim
base
upon
noth
scenario
ie
cc
alon
versu
rmix
tm
alon
result
implement
rmix
tm
retent
cc
capabl
would
serv
increas
overal
cost
rmix
tm
approach
summari
conclud
rmix
tm
system
compar
sensit
cc
detect
parainfluenza
serotyp
influenza
ab
dramat
reduc
ttd
rsv
rmix
tm
system
significantli
sensit
time
cc
neither
appear
offer
diagnost
benefit
dat
sensit
rmix
tm
adenoviru
detect
clinic
materi
significantli
lower
cc
final
technic
logist
advantag
rmix
tm
system
exist
altern
methodolog
must
remain
place
identif
recogn
viral
respiratori
pathogen
includ
cmv
hsv
picornavirus
desir
